After a six-year absence from the RSNA technical spotlight MRIvendor Fonar is planning to return to radiology's spotlight witha family of new MRI scanners and momentum from its recent courtvictories in patent litigation with GE. In a jury trial in
After a six-year absence from the RSNA technical spotlight MRIvendor Fonar is planning to return to radiology's spotlight witha family of new MRI scanners and momentum from its recent courtvictories in patent litigation with GE.
In a jury trial in federal court earlier this year, Fonar ofMelville, NY, won a ruling that GE infringed on two patents grantedto Fonar founder Dr. Raymond Damadian. The two sides continueto wrangle over appeals to the verdict (SCAN 10/25/95).
Fonar hopes to use the jury award, along with cash from a settlementof litigation with Hitachi, to fund a comeback in the MRI industry.At the RSNA meeting, Fonar will display its Quad family, whichincludes the 0.35-tesla Quad 7000 and the 0.6-tesla Quad 12000.
Fonar will emphasize the openness of Quad 7000 and its suitabilityfor obese and claustrophobic patients. The company also plansto highlight Quad 7000's potential in delivering cost-effectiveMR mammography.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.